Athos Therapeutics Highlights Potential of AI-Generated, First-in-Class, ATH-063 for Inflammatory Bowel Disease in a Featured Discussion
Los Angeles, CA – March 9, 2026 – Athos Therapeutics, Inc. (“Athos”), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today spotlighted the promising profile of its lead candidate ATH-063, a novel, first-in-class oral G9A methyltransferase inhibitor for the treatment of Inflammatory […]
Dimitrios Iliopoulos, CEO of AthosOmics.AI, to Speak at The Montgomery Summit on AI-Driven Drug Discovery
Los Angeles, CA – March 6, 2026 – Dr. Dimitrios Iliopoulos, CEO and co-founder of AthosOmics.AI (part of Athos Therapeutics Inc.), will participate as a featured speaker in a high-profile panel discussion at The Montgomery Summit, taking place March 10-11, 2026, at the Fairmont Miramar Hotel & Bungalows in Santa Monica. The session, titled “AI-Driven […]
A new publication from IBM and Athos Therapeutics (member of the Quantum for Healthcare and Life Sciences consortium)
A new 2026 article in Nature Reviews Molecular Cell Biology (click to view) from IBM researchers and the Quantum for Healthcare Life Sciences Consortium (Athos is a member and contributor), details how quantum computers, which use quantum physics rules to solve problems far faster than regular computers, can be leveraged with normal computers, AI, and multi-omics analysis to tackle […]
Scientific Recognition at Crohn’s & Colitis Congress 2026
We are pleased to share that our presentation at the Crohn’s & Colitis Congress 2026, held January 22–24 in Las Vegas, was recognized with a “Poster of Distinction” award (attached photos). The conference was organized by Crohn’s & Colitis Foundation and the American Gastroenterology Association and had ~2,000 attendees, primarily from US universities and big pharma. The honored poster was […]
Athos Therapeutics Receives US FDA Authorization to begin Multi-Center Phase 2 Clinical Trial of ATH-063 in Patients with Ulcerative Colitis
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease LOS ANGELES, January 21, 2026 — Athos Therapeutics, Inc. (“Athos”), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, […]
Athos Therapeutics and Xeptiva Therapeutics Announce Partnership to Discover Vaccine Biomarkers with the AthosOmics.AI Platform
The companies will use clinical trial plasma samples and data to drive the AthosOmics.AI platform to identify efficacy biomarkers for Xeptiva’s lead experimental therapeutic vaccine for canine osteoarthritis chronic pain 10 November 2025, 11:00 am ET LOS ANGELES, November 10, 2025 — Athos Therapeutics, Inc. (“Athos”), an AI software and clinical stage biotechnology company pioneering […]
“Athos Omics AI”: A Revolutionary Software Platform to Analyze Omics Data Across Industries
Powerful omics analytics for drug, agriculture, food, beverage, and cosmetics development LOS ANGELES, July 14, 2025 — Athos Therapeutics, Inc. (“Athos”), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, announced the launch of a new website that details “Athos Omics AI” their […]
AI-driven solutions for multi-omics analysis
A Co-Founder of Athos Therapeutics, Dr. Michael E. Jung, Wins the National Academy of Sciences Award for Chemistry in Service to Society
30 April 2025, 11:30 am ET LOS ANGELES, April 30, 2025 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, is honored to announce that Dr. Michael E. Jung, a co-founder of Athos, was awarded the National Academy of Sciences Award for […]
CIOs look beyond ‘Big 3’ cloud providers for AI innovation
